Identification of a potential pharmacological sanctuary for HIV type 1 in a fraction of CD4+ primary cells

AIDS Research and Human Retroviruses

Volumn 26, Issue 1, 2010, Pages 79-88

  Valentin, Antonio ^a   Morrow, Matthew ^a   Poirier, Richard H ^a   Aleman, Karen ^b   Little, Richard ^b   Yarchoan, Robert ^b   Pavlakis, George N ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; CHEMOKINE RECEPTOR CCR5; GLYCOPROTEIN P; INDINAVIR; PROTEINASE INHIBITOR; RITONAVIR;

ANTIVIRAL ACTIVITY; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MEMORY CELL; NATURAL KILLER CELL; PERIPHERAL BLOOD MONONUCLEAR CELL; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; T LYMPHOCYTE; VIRUS REPLICATION;

BIOLOGICAL TRANSPORT, ACTIVE; CD4-POSITIVE T-LYMPHOCYTES; DRUG RESISTANCE, VIRAL; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; P-GLYCOPROTEIN;

EID: 76449103996     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/aid.2009.0044     Document Type: Article

References (71)

1. Gulick RM, Mellors JW, Havlir D, et al.: Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N Engl J Med 1997;337:734-739.
2. Ho DD, Neumann AU, Perelson AS, Chen W, Leonard JM, and Markowitz M: Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 1995;373:123-126.
3. Perelson AS, Neumann AU, Markowitz M, Leonard JM, and Ho DD: HIV-1 dynamics in vivo: Virion clearance rate, infected cell life-span, and viral generation time. Science 1996;271:1582-1586.
4. Perelson AS, Essunger P, Cao Y, et al.: Decay characteristics of HIV-1-infected compartments during combination therapy. Nature 1997;387:188-191.
5. Wei X, Ghosh SK, Taylor ME, et al.: Viral dynamics in human immunodeficiency virus type 1 infection. Nature 1995;373:117-122.
6. Chun TW, Stuyver L, Mizell SB, et al.: Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy. Proc Natl Acad Sci USA 1997;94:13193-13197.
7. Chun TW, Engel D, Berrey MM, Shea T, Corey L, and Fauci AS: Early establishment of a pool of latently infected, resting CD4(+) T cells during primary HIV-1 infection. Proc Natl Acad Sci USA 1998;95:8869-8873.
8. Finzi D, Hermankova M, Pierson T, et al.: Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science 1997;278:1295-1300.
9. Finzi D, Blankson J, Siliciano JD, et al.: Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy. Nat Med 1999;5:512-517.
10. Wong JK, Hezareh M, Gunthard HF, et al.: Recovery of replication- competent HIV despite prolonged suppression of plasma viremia. Science 1997;278:1291-1295.
11. Martinez-Picado J, DePasquale MP, Kartsonis N, et al.: Antiretroviral resistance during successful therapy of HIV type 1 infection. Proc Natl Acad Sci USA 2000;97:10948-10953.
12. Martinez-Picado J, Savara AV, Shi L, Sutton L, and D'Aquila RT: Fitness of human immunodeficiency virus type 1 protease inhibitor-selected single mutants. Virology 2000;275: 318-322.
13. Condra JH, Schleif WA, Blahy OM, et al.: In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors. Nature 1995;374:569-571.
14. Emini EA, Schleif WA, Deutsch P, and Condra JH: In vivo selection of HIV-1 variants with reduced susceptibility to the protease inhibitor L-735,524 and related compounds. Adv Exp Med Biol 1996;394:327-331.
15. Grossman Z, Polis M, Feinberg MB, et al.: Ongoing HIV dissemination during HAART. Nat Med 1999;5:1099-1104.
16. Dornadula G, Zhang H, VanUitert B, et al.: Residual HIV-1 RNA in blood plasma of patients taking suppressive highly active antiretroviral therapy. JAMA 1999;282:1627-1632.
17. Furtado MR, Callaway DS, Phair JP, et al.: Persistence of HIV-1 transcription in peripheral-blood mononuclear cells in patients receiving potent antiretroviral therapy. N Engl J Med 1999;340:1614-1622.
18. Natarajan V, Bosche M, Metcalf JA, Ward DJ, Lane HC, and Kovacs JA: HIV-1 replication in patients with undetectable plasma virus receiving HAART. Highly active antiretroviral therapy. Lancet 1999;353:119-120.
19. Zhang L, Ramratnam B, Tenner-Racz K, et al.: Quantifying residual HIV-1 replication in patients receiving combination antiretroviral therapy. N Engl J Med 1999;340:1605-1613.
20. Lafeuillade A, Solas C, Halfon P, Chadapaud S, Hittinger G, and Lacarelle B: Differences in the detection of three HIV-1 protease inhibitors in non-blood compartments: Clinical correlations. HIV Clin Trials 2002;3:27-35.
21. Foudraine NA, Hoetelmans RM, Lange JM, et al.: Cerebrospinal-fluid HIV-1 RNA and drug concentrations after treatment with lamivudine plus zidovudine or stavudine. Lancet 1998;351:1547-1551.
22. Kashuba AD, Dyer JR, Kramer LM, Raasch RH, Eron JJ, and Cohen MS: Antiretroviral-drug concentrations in semen: Implications for sexual transmission of human immunodeficiency virus type 1. Antimicrob Agents Chemother 1999; 43:1817-1826.
23. Schrager LK and D'Souza MP: Cellular and anatomical reservoirs of HIV-1 in patients receiving potent antiretroviral combination therapy. JAMA 1998;280:67-71.
24. Taylor S and Pereira A: Penetration of HIV-1 protease inhibitors into CSF and semen. HIV Med 2000;1(Suppl 2):18-22.
25. Van Praag RM, Weverling GJ, Portegies P, et al.: Enhanced penetration of indinavir in cerebrospinal fluid and semen after the addition of low-dose ritonavir. AIDS 2000;14:1187-1194.
26. Zhu T, Wang N, Carr A, et al.: Genetic characterization of human immunodeficiency virus type 1 in blood and genital secretions: Evidence for viral compartmentalization and selection during sexual transmission. J Virol 1996;70:3098-3107.
27. Ueda K, Cornwell MM, Gottesman MM, et al.: The mdr1 gene, responsible for multidrug-resistance, codes for P-glycoprotein. Biochem Biophys Res Commun 1986;141: 956-962.
28. Thiebaut F, Tsuruo T, Hamada H, Gottesman MM, Pastan I, and Willingham MC: Cellular localization of the multidrugresistance gene product P-glycoprotein in normal human tissues. Proc Natl Acad Sci USA 1987;84:7735-7738.
29. Chaudhary PM, Mechetner EB, and Roninson IB: Expression and activity of the multidrug resistance P-glycoprotein in human peripheral blood lymphocytes. Blood 1992;80:2735-2739.
30. Drach D, Zhao S, Drach J, et al.: Subpopulations of normal peripheral blood and bone marrow cells express a functional multidrug resistant phenotype. Blood 1992;80:2729-2734.
31. Egashira M, Kawamata N, Sugimoto K, Kaneko T, and Oshimi K: P-glycoprotein expression on normal and abnormally expanded natural killer cells and inhibition of Pglycoprotein function by cyclosporin A and its analogue, PSC833. Blood 1999;93:599-606.
32. Ludescher C, Pall G, Irschick EU, and Gastl G: Differential activity of P-glycoprotein in normal blood lymphocyte subsets. Br J Haematol 1998;101:722-727.
33. Choo EF, Leake B, Wandel C, et al.: Pharmacological inhibition of P-glycoprotein transport enhances the distribution of HIV-1 protease inhibitors into brain and testes. Drug Metab Dispos 2000;28:655-660.
34. Jones K, Bray PG, Khoo SH, et al.: P-Glycoprotein and transporter MRP1 reduce HIV protease inhibitor uptake in CD4 cells: Potential for accelerated viral drug resistance? AIDS 2001;15:1353-1358.
35. Lee CG, Gottesman MM, Cardarelli CO, et al.: HIV-1 protease inhibitors are substrates for the MDR1 multidrug transporter. Biochemistry 1998;37:3594-3601.
36. Srinivas RV, Middlemas D, Flynn P, and Fridland A: Human immunodeficiency virus protease inhibitors serve as substrates formultidrug transporter proteinsMDR1 andMRP1 but retain antiviral efficacy in cell lines expressing these transporters. Antimicrob Agents Chemother 1998;42:3157-3162.
37. Hoggard PG and Back DJ: Intracellular pharmacology of nucleoside analogues and protease inhibitors: Role of transporter molecules. Curr Opin Infect Dis 2002;15:3-8.
38. Valentin A, Lu W, Rosati M, et al.: Dual effect of interleukin 4 on HIV-1 expression: Implications for viral phenotypic switch and disease progression. Proc Natl Acad Sci USA 1998;95:8886-8891.
39. Chen Y and Simon SM: In situ biochemical demonstration that P-glycoprotein is a drug efflux pump with broad specificity. J Cell Biol 2000;148:863-870.
40. Valentin A, Rosati M, Patenaude DJ, et al.: Persistent HIV-1 infection of natural killer cells in patients receiving highly active antiretroviral therapy. Proc Natl Acad Sci USA 2002;99:7015-7020.
41. Andreana A, Aggarwal S, Gollapudi S, Wien D, Tsuruo T, and Gupta S: Abnormal expression of a 170-kilodalton P-glycoprotein encoded by MDR1 gene, a metabolically active efflux pump, in CD4+ and CD8+ T cells from patients with human immunodeficiency virus type 1 infection. AIDS Res Hum Retroviruses 1996;12:1457-1462.
42. Lucia MB, Cauda R, Landay AL, Malorni W, Donelli G, and Ortona L: Transmembrane P-glycoprotein (P-gp/P-170) in HIV infection: Analysis of lymphocyte surface expression and drug-unrelated function. AIDS Res Hum Retroviruses 1995;11:893-901.
43. Meaden ER, Hoggard PG, Maher B, Khoo SH, and Back DJ: Expression of P-glycoprotein and multidrug resistanceassociated protein in healthy volunteers and HIV-infected patients. AIDS Res Hum Retroviruses 2001;17:1329-1332.
44. Lee CG, Ramachandra M, Jeang KT, Martin MA, Pastan I, and Gottesman MM: Effect of ABC transporters on HIV-1 infection: Inhibition of virus production by the MDR1 transporter. Faseb J 2000;14:516-522.
45. Speck RR, Yu XF, Hildreth J, and Flexner C: Differential effects of P-glycoprotein and multidrug resistance protein-1 on productive human immunodeficiency virus infection. J Infect Dis 2002;186:332-340.
46. Cato A, 3rd, Qian J, Hsu A, et al.: Pharmacokinetic interaction between ritonavir and didanosine when administered concurrently to HIV-infected patients. J Acquir Immune Defic Syndr Hum Retrovirol 1998;18:466-472.
47. Gatti G, Pontali E, Boni S, De Pascalis CR, Bassetti M, and Bassetti D: The relationship between ritonavir plasma trough concentration and virological and immunological response in HIV-infected children. HIV Med 2002;3:125-128.
48. Gatti G, Di Biagio A, Casazza R, et al.: The relationship between ritonavir plasma levels and side-effects: Implications for therapeutic drug monitoring. AIDS 1999;13:2083-2089.
49. Kilby JM, Hill A, and Buss N: The effect of ritonavir on saquinavir plasma concentration is independent of ritonavir dosage: Combined analysis of pharmacokinetic data from 97 subjects. HIV Med 2002;3:97-104.
50. Markowitz M, Saag M, Powderly WG, et al.: A preliminary study of ritonavir, an inhibitor of HIV-1 protease, to treat HIV-1 infection. N Engl J Med 1995;333:1534-1539.
51. Benet LZ, Izumi T, Zhang Y, Silverman JA, and Wacher VJ: Intestinal MDR transport proteins and P-450 enzymes as barriers to oral drug delivery. J Control Release 1999;62: 25-31.
52. Wacher VJ, Silverman JA, Zhang Y, and Benet LZ: Role of P-glycoprotein and cytochrome P450 3A in limiting oral absorption of peptides and peptidomimetics. J Pharm Sci 1998;87:1322-1330.
53. Washington CB, Duran GE, Man MC, Sikic BI, and Blaschke TF: Interaction of anti-HIV protease inhibitors with the multidrug transporter P-glycoprotein (P-gp) in human cultured cells. J Acquir Immune Defic Syndr Hum Retrovirol 1998;19:203-209.
54. Kim AE, Dintaman JM, Waddell DS, and Silverman JA: Saquinavir, an HIV protease inhibitor, is transported by P-glycoprotein. J Pharmacol Exp Ther 1998;286:1439-1445.
55. Chaillou S, Durant J, Garraffo R, et al.: Intracellular concentration of protease inhibitors in HIV-1-infected patients: Correlation with MDR-1 gene expression and low dose of ritonavir. HIV Clin Trials 2002;3:493-501.
56. Kim RB, Fromm MF, Wandel C, et al.: The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors. J Clin Invest 1998;101:289-294.
57. Jones K, Hoggard PG, Sales SD, Khoo S, Davey R, and Back DJ: Differences in the intracellular accumulation of HIV protease inhibitors in vitro and the effect of active transport. AIDS 2001;15:675-681.
58. Janneh O, Jones E, Chandler B, Owen A, and Khoo SH: Inhibition of P-glycoprotein and multidrug resistanceassociated proteins modulates the intracellular concentration of lopinavir in cultured CD4 T cells and primary human lymphocytes. J Antimicrob Chemother 2007;60:987-993.
59. Bossi P, Mouroux M, Yvon A, et al.: Polymorphism of the human immunodeficiency virus type 1 (HIV-1) protease gene and response of HIV-1-infected patients to a protease inhibitor. J Clin Microbiol 1999;37:2910-2912.
60. Fellay J, Marzolini C, Meaden ER, et al.: Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug resistance transporter 1: A pharmacogenetics study. Lancet 2002;359:30-36.
61. Zeldin RK and Petruschke RA: Pharmacological and therapeutic properties of ritonavir-boosted protease inhibitor therapy in HIV-infected patients. J Antimicrob Chemother 2004;53:4-9.
62. Eagling VA, Back DJ, and Barry MG: Differential inhibition of cytochrome P450 isoforms by the protease inhibitors, ritonavir, saquinavir and indinavir. Br J Clin Pharmacol 1997;44:190-194.
63. Lucia MB, Rutella S, Leone G, Vella S, and Cauda R: HIVprotease inhibitors contribute to P-glycoprotein efflux function defect in peripheral blood lymphocytes from HIVpositive patients receiving HAART. J Acquir Immune Defic Syndr 2001;27:321-330.
64. Profit L, Eagling VA, and Back DJ: Modulation of Pglycoprotein function in human lymphocytes and Caco-2 cell monolayers by HIV-1 protease inhibitors. AIDS 1999;13: 1623-1627.
65. Van Heeswijk RP, Veldkamp AI, Hoetelmans RM, et al.: The steady-state plasma pharmacokinetics of indinavir alone and in combination with a low dose of ritonavir in twice daily dosing regimens in HIV-1-infected individuals. AIDS 1999;13:F95-99.
66. Bilello JA, Bilello PA, Stellrecht K, et al.: Human serum alpha 1 acid glycoprotein reduces uptake, intracellular concentration, and antiviral activity of A-80987, an inhibitor of the human immunodeficiency virus type 1 protease. Antimicrob Agents Chemother 1996;40:1491-1497.
67. Molla A, Korneyeva M, Gao Q, et al.: Ordered accumulation of mutations in HIV protease confers resistance to ritonavir. Nat Med 1996;2:760-766.
68. Sham HL, Kempf DJ, Molla A, et al.: ABT-378, a highly potent inhibitor of the human immunodeficiency virus protease. Antimicrob Agents Chemother 1998;42:3218-3224.
69. Ifergan I, Bernard NF, Bruneau J, Alary M, Tsoukas CM, and Roger M: Allele frequency of three functionally active polymorphisms of the MDR-1 gene in high-risk HIV-negative and HIV-positive Caucasians. AIDS 2002;16:2340-2342.
70. Ritter CA, Jedlitschky G, Meyer zu Schwabedissen H, Grube M, Kock K, and Kroemer HK: Cellular export of drugs and signaling molecules by the ATP-binding cassette transporters MRP4 (ABCC4) and MRP5 (ABCC5). Drug Metab Rev 2005;37:253-278.
71. Schuetz EG and Schinkel AH: Drug disposition as determined by the interplay between drug-transporting and drug-metabolizing systems. J Biochem Mol Toxicol 1999;13: 219-222.